Sugi Predict

Sugi Predict / Compounds / Methimepip

Methimepip

Methimepip

SCHEMBL8320104

CN1CCC(Cc2c[nH]cn2)CC1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 5/20 0.51
▸ HRH4 Q9H3N8 2/20 0.51
▸ ACHE P22303 2/20 0.39
▸ NCF1 P14598 1/20 0.38
▸ MAPK7 Q13164 1/20 0.34
▸ HTR6 P50406 4/20 0.34
▸ ROCK2 O75116 1/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ CDC42BPB Q9Y5S2 1/20 0.33
▸ DRD2 P14416 1/20 0.32
▸ BRD9 Q9H8M2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28079718 0.85 — —
SCHEMBL22338857 0.84 HRH3 (0.54) HRH3HRH4
SCHEMBL14307810 0.82 HRH4 (0.42) HRH3HRH4HTR6
SCHEMBL14143044 0.81 HRH3 (0.35) HRH3HRH4
SCHEMBL14140514 0.81 HRH3 (0.32) HRH3HRH4
SCHEMBL6449281 0.80 HRH4 (0.44) HRH3HRH4HTR6
Immepip SCHEMBL6347746 0.79 HRH3 (0.46) HRH3HRH4
Immepip SCHEMBL6354845 0.77 HRH3 (0.47) HRH3HRH4
Immepip SCHEMBL6605805 0.77 HRH3 (0.45) HRH3HRH4
SCHEMBL12048473 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240269123-A1 MUSCLE REGENERATION PROMOTER SATO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 — — US claimed
WO-2022255250-A1 MUSCLE REGENERATION PROMOTER 佐藤製薬株式会社 2022-12-08 — — WO claimed
US-11439624-B2 Promoting sleep using AT1 receptor blockers University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2022-09-13 — — US claimed
US-20240269123-A1 MUSCLE REGENERATION PROMOTER SATO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 — — US disclosed
US-20230065814-A1 CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS ASCENDIS PHARMA A/S (DK) 2023-03-02 — — US disclosed
US-20230053746-A1 IL-17 LIGANDS AND USES THEREOF DICE MOLECULES SV, INC. 2023-02-23 — — US disclosed
US-11564970-B2 Compositions and methods for combinatorial drug discovery in nanoliter droplets THE BROAD INSTITUTE, INC. (US) 2023-01-31 — — US disclosed
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 — — US disclosed
WO-2022255250-A1 MUSCLE REGENERATION PROMOTER 佐藤製薬株式会社 2022-12-08 — — WO disclosed
US-20220305129-A1 CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS ASCENDIS PHARMA A/S (DK) 2022-09-29 — — US disclosed
US-11439624-B2 Promoting sleep using AT1 receptor blockers University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2022-09-13 — — US disclosed
EP-4031531-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 — — EP disclosed
CN-114787135-A Substituted imidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 — — CN disclosed
US-11383084-B2 Treatment of dermatological conditions via neuromodulation PALO ALTO INVESTORS (US) 2022-07-12 — — US disclosed
EP-3986472-A1 CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS Ascendis Pharma A/S (DK) 2022-04-27 — — EP disclosed
EP-3986477-A1 CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS Ascendis Pharma A/S (DK) 2022-04-27 — — EP disclosed
WO-2021055612-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL-BioTech Investments, Inc. (US) 2021-03-25 — — WO disclosed
US-20200247785-A1 IL-17 Ligands And Uses Thereof DICE MOLECULES SV, INC. 2020-08-06 — — US disclosed
WO-2004066960-A2 COMBINATION OF H1, H3 AND H4 RECEPTOR ANTAGONISTS FOR TREATMENT OF ALLERGIC AND NON-ALLERGIC PULMONARY INFLAMMATION, CONGESTION AND ALLERGIC RHINITIS SCHERING CORPORATION (US) 2004-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053746-A1 IL-17 LIGANDS AND USES THEREOF IL17A, IL2, IL15 HRH3 2645/4885HRH4 2797/4885ACHE 4779/4885
US-20200247785-A1 IL-17 Ligands And Uses Thereof IL17A, IL2, IL15 HRH3 2645/4885HRH4 2797/4885ACHE 4779/4885
US-20220305129-A1 CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS NQO1, ABCB1, NCL HRH3 503/4885HRH4 269/4885ACHE 632/4885
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 HRH3 256/4885HRH4 284/4885ACHE 722/4885
US-20230065814-A1 CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS NQO1, NCL, ABCB1 HRH3 882/4885HRH4 636/4885ACHE 775/4885
US-20240269123-A1 MUSCLE REGENERATION PROMOTER MUSK, HRH3, HGF HRH3 2/4885HRH4 7/4885ACHE 365/4885
US-11564970-B2 Compositions and methods for combinatorial drug discovery in nanoliter droplets RAB5IF, LIPA, CLTB HRH3 3166/4885HRH4 3614/4885ACHE 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.